The International Diabetes Federation estimates that approximately 0.4% of the Belgian population is diagnosed with type 1 diabetes mellitus, which is similar to other industrialized countries. The prevalence of transgenderism is estimated at 0.6% to 0.7% of all adults in Western populations. In this study, we evaluated whether there was an increased prevalence of type 1 diabetes mellitus in transgender people in the local cohort. Medical records of transgender patients were analyzed retrospectively. From January 1, 2007 until October 10, 2016, 1,081 transgender patients presented at a tertiary reference center to start hormonal treatment. Nine of these 1,081 patients were previously diagnosed with type 1 diabetes mellitus and 1 was diagnosed with latent autoimmune diabetes in adults. A 2.3-fold higher prevalence of type 1 diabetes mellitus was observed in transgender patients. We concluded that type 1 diabetes mellitus was more prevalent in transgender patients than one would expect from population prevalences. This could be a spurious result in a local cohort, because a causal relation seems unlikely, but our finding might encourage other centers to investigate this putative association.
INTRODUCTION
At the Ghent University Hospital outpatient endocrine clinic (Ghent, Belgium), recognized as a tertiary referral center for transgender care, we perceived a relatively high prevalence of type 1 diabetes mellitus in transgender individuals seeking genderaffirming hormonal treatment. However, there is no known association between type 1 diabetes mellitus and transgenderism.
In Belgium, the prevalence of type 1 diabetes mellitus in the Belgian population is estimated at 0.4% by the International Diabetes Federation (IDF), which is similar to the prevalence rate of type 1 diabetes mellitus in the Netherlands (0.48%). 1 Exact incidence rates are unknown, because newly diagnosed cases are not systematically documented in Belgium.
Previous studies on the prevalence of transgenderism reported mainly on the prevalence of transgender persons looking for gender-affirming care, which led to an underestimation of the prevalence of transgenderism. 2 In a recent study by Van Caenegem et al, 2 the overall prevalence of transgenderism in Flanders, Belgium was estimated at 0.6% to 0.7% of all adults.
Theoretically, the options for gender affirmation include social, psychological, hormonal, and surgical transitioning, although decisions regarding gender-affirmative therapy should be made for the individual. Options for gender-affirming hormonal treatment include testosterone administration (intramuscular injections or gel applications) in transmen and estrogens (orally or transdermally administrated) and antiandrogens in transwomen.
Given the relatively low prevalence of transgenderism and type 1 diabetes mellitus, combined prevalence in one person is expected to be rare. Therefore, we evaluated whether the number of transgender persons with the comorbidity of type 1 diabetes mellitus was higher than expected in our center.
METHODS
To evaluate a possible association between type 1 diabetes mellitus and transgenderism in our local cohort, medical records of transgender persons were analyzed retrospectively. To investigate whether the difference between expected and observed numbers of transgender persons presenting with type 1 diabetes mellitus was significant, a c 2 statistical test ([observed À expected] 2 /expected) was performed using IDF estimates.
RESULTS
From January 1, 2007 until October 10, 2016, 1,081 transgender persons and 372 patients with type 1 diabetes mellitus presented at the endocrinology department of our hospital. We found that 9 of 1,081 transgender persons were previously diagnosed with type 1 diabetes mellitus and 1 person was previously diagnosed with latent autoimmune diabetes of adulthood, a form of type 1 diabetes mellitus that develops later in adulthood (Table 1) . Of these transgender individuals, eight (80%) were transwomen (male-to-female transgender persons) and two (20%) were transmen (female-to-male transgender persons). Their mean age was 36.7 years (range ¼ 19e53 years) and mean age at diagnosis of type 1 diabetes mellitus was 15.7 years (range ¼ 3e29 years). Five transgender persons recalled their first feelings of gender incongruence at a mean age of 6.8 years (range ¼ 4e13 years). For two persons, this information was not found in the medical records, one did not recall, and two persons responded that they felt this way since "early childhood." The reported trans-persons started gender-affirming hormonal therapy at mean age of 29.4 years (range ¼ 19e50 years). The expected number of persons previously diagnosed with type 1 diabetes mellitus presenting for transgender care was 4.32 (1,081 Â 0.4%). The calculated c 2 statistic of 7.47 (P ¼ .006) indicated that the higher prevalence of type 1 diabetes mellitus in transgender individuals (0.92%) was highly significant (2.3 times higher; Figure 1 ).
DISCUSSION
We found an increased number of transgender persons with type 1 diabetes mellitus at our center compared with the expectation based on the combined prevalence of transgenderism and type 1 diabetes mellitus in Western populations. Because not all transgender persons wish or search for gender-affirming hormonal treatment, this number could be an understimation. 2 The predominant effector mechanism of type 1 diabetes mellitus is autoimmunity, although the primary cause is unknown. 3 There are case reports describing other autoimmune diseases in transgender persons, although those researchers correlated their observations with the administered hormonal therapy, whereas in our patients type 1 diabetes mellitus was already prevalent before initiation of hormonal therapy. 4, 5 A possible pathophysiologic mechanism behind the observed correlation between type 1 diabetes mellitus and transgenderism is difficult to fathom, if only because the etiology of transgenderism remains unclear. Etiologic theories include atypical Table 1 . gender development during childhood and parental and familial, genetic, and biological factors. 6 Because the incidence of type 1 diabetes mellitus is known to peak during puberty, 3 a time when serum sex hormone levels increase, one could hypothesize a correlation between the administration of cross-sex hormones in transgender persons and the occurrence of type 1 diabetes mellitus. However, the trans-persons in our study cohort had known type 1 diabetes mellitus before they initiated cross-sex hormone therapy. So far, no studies have shown autoimmunity to be a cause for gender dysphoria.
Another possible explanation for the correlation between type 1 diabetes mellitus and gender dysphoria might be that the prolonged psychological stress of the gender dysphoria-mostly present at a young age in our cohort-is a precipitating factor for type 1 diabetes mellitus. Several studies have provided evidence for an association between psychological stress and type 1 diabetes mellitus.
7e13 Many transgender persons experience mental health issues and chronic stress (often called "minority stress") owing to internalized stigma, victimization, social rejection, and lack of social support.
14e16 This chronic psychoneurotic distress decreases markedly after the initiation of gender-affirming hormonal therapy.
17e19 Emotional problems such as depression and anxiety are frequently reported in trans-children and trans-adolescents, 20 with ostracism and peer victimization as risk factors accounting for co-occurring general psychopathology in gender non-conforming children and adolescents. 21 Different types of stress are known to cause excessive release of stress hormones (cortisol, catecholamines), which can increase insulin requirements and increase stress on pancreatic b-cells. Another hypothesis is that stress accelerates the autoimmune destruction of pancreatic b-cells by affecting the immune system. 22 To date, to our knowledge, there is no literature on the management of type 1 diabetes mellitus in transgender patients. We recommend transgender patients seek care for their type 1 diabetes mellitus in a center where health care providers treat transgender persons with respect and dignity, independent of their personal views of gender incongruence.
As for the strengths and weaknesses of this study, there might be a selection bias. The reported transgender persons visited a diabetologist close to their home for the management of type 1 diabetes mellitus. None of them were treated for type 1 diabetes mellitus in our hospital. However, the fact that a trans-person is seen by a peripheral endocrinologist for follow-up of type 1 diabetes mellitus can increase the possibility that this person would be referred to an endocrinologist specialized in transgender care.
CONCLUSIONS
Type 1 diabetes mellitus seemed more prevalent in transgender patients visiting a tertiary endocrinology center than one would expect from population prevalence. This could be a spurious result in a local cohort, because a causal relation seems unlikely and a pathophysiologic mechanism is difficult to fathom, but our findings might encourage other centers to investigate this association in larger cohorts.
